查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1916507

全球体外诊断市场：市场规模、份额、成长率、产业分析、按类型、应用和地区划分的考量、未来预测（2026-2034）

In vitro Diagnostics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 290 Pages | 商品交期: 请询问到货日

价格

体外诊断 (IVD) 市场成长因子

全球体外诊断 (IVD) 市场规模预计在 2025 年将达到 777.3 亿美元，2026 年将成长至 818.3 亿美元，到 2034 年将达到 1356.5 亿美元，在预测期（2026-2034 年）内将达到 1356.5 亿美元，在预测期（2026-2034 年）内复合成长率为 6.50%。凭藉先进的医疗基础设施、优惠的报销政策以及主要诊断设备製造商的强大影响力，北美在2025年将以37.70%的市场份额引领全球体外诊断（IVD）市场。

体外诊断设备是用于分析血液、尿液、唾液和组织等生物样本的医疗诊断工具，其用途包括检测疾病、监测治疗效果和进行健康检查。据英国体外诊断协会（BIDA）称，体外诊断检测影响约70%的临床决策，凸显了其在现代医疗保健系统中的关键作用。

市场驱动因素

慢性病和传染病的增加是推动市场成长的主要因素。根据美国疾病管制与预防中心 (CDC) 的数据，2022 年美国结核病病例数将增加 5%，达到 8,300 例。此外，美国国家生物技术资讯中心 (NCBI) 的数据显示，到 2023 年，全球慢性B型肝炎病毒感染率将达到 3.2%（2.57 亿例）。

人口老化将进一步增加所需的检测数量。在中国，预计到 2023 年，60 岁及以上人口将达到约 2.97 亿，这将推动心血管、肾臟和代谢性疾病诊断监测的需求。政府加强支持力度也在推动检测的普及。 2023 年 10 月，世界卫生组织 (WHO) 发布了《2023 年基本诊断清单》，敦促各国加强初级和二级医疗保健机构的诊断服务。

市场限制因子

新兴国家采用此技术受限于高昂的设备和维修成本。 RT-PCR 系统的价格从 15,000 美元到超过 90,000 美元不等，小型医院和实验室难以负担。此外，对熟练人员的需求增加了营运成本，阻碍了资源匮乏地区广泛采用该技术。

市场机会

分子诊断技术因其高灵敏度和快速检测能力而展现出巨大的市场机会。 PCR 和次世代定序等技术能够以极少的样本量实现早期诊断。 2023 年 3 月，DiaSorin 的 Simplexa COVID-19 和甲型/乙型流感直接检测试剂盒获得 FDA 批准，进一步拓展了其分子检测产品组合。

肿瘤生物标记检测和个人化医疗计画的扩展也推动了先进诊断平台的应用。癌症筛检计画的扩展和基因组检测的广泛应用，正在推动已开发国家和新兴国家分子诊断检测数量的成长。

市场挑战

一些国家不利的报销政策限制了检测的普及。在巴西和墨西哥，针对高级分子检测的保险覆盖仍然不足。据美国国家生物技术资讯中心 (NCBI) 称，罕见疾病参考中心每三个月仅为每位患者提供 142 美元，不足以支付高级基因组检测的费用。监管的复杂性、供应链中断和激烈的市场竞争进一步加剧了营运方面的挑战。

市场趋势

即时检测 (POC) 因其快速出结果和较低的基础设施需求而迅速普及。 2023 年 1 月，Cipla 推出了 Cippoint POC 设备，加强了分散式诊断。 2022 年 6 月，BD 的 COVID-19、流感和呼吸道合胞病毒 (RSV) 组合检测板获得了 CE 认证，支持了多重检测的普及。

自动化和人工智慧技术的整合正在提升临床实验室的工作流程效率、诊断准确性和样本处理量。

依细分市场分析

依产品类型

由于慢性病监测和即时检测 (POC) 试剂盒的高检测量，试剂和耗材在 2024 年占据市场主导地位。 2021 年 2 月，赛默飞世尔科技 (Thermo Fisher) 推出了用于高通量检测的 TaqPath COVID-19 HT 试剂盒。由于自动化升级，例如 BD 公司于 2023 年 6 月推出的 FACSDuet Premium 样本製备系统，预计设备领域将保持稳定成长。

依科技

由于传染病和肿瘤检测的增加，分子诊断将在 2024 年成为主流。 Seegene 于 2023 年 12 月获得 ISO 45001 PCR 诊断认证。由于代谢性疾病筛检的增加，临床化学也稳定发展。

依样本类型

血液样本将在 2024 年成为主流。这是因为美国每年进行约 20 亿次血液检测。由于非侵入性诊断技术的创新，尿液和唾液检测的数量也在增加。

按地点

由于复杂的检测需求和自动化方面的投资，实验室将成为主流。由于对快速传染病筛检和紧急检测的需求不断增长，即时检测 (POC) 环境正在迅速扩展。

按应用领域

传染病诊断将在2024年占据主导地位。根据世界卫生组织估计，2023年全球结核病病例将达1,080万例。此外，由于基于生物标记的癌症筛检的普及，肿瘤诊断领域也呈现强劲成长势头。

按最终使用者

临床实验室将在2024年占据主导地位，美国约有322,488家实验室。医院越来越多地采用糖尿病、妊娠和急诊检测。

区域展望

预计北美地区2025年将达到293.3亿美元，2026年将达到309.2亿美元，其中美国2026年将达到279.8亿美元。欧洲仍将维持第二大市场地位，预计德国2026年将达55亿美元，英国将达38.3亿美元。亚太地区2026年将达189.4亿美元，其次是中国（66.1亿美元）、日本（43.2亿美元）和印度（33.7亿美元）。拉丁美洲市场规模预计在 2026 年达到 62.2 亿美元，海湾合作委员会 (GCC) 市场规模预计在 2026 年达到 42.5 亿美元。

目录

第一章：引言

第二章：执行摘要

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇

第四章：关键考虑因素

  • 各国和地区主要疾病盛行率（2025 年）
  • 主要公司新产品发布
  • 近期产业趋势：併购
  • 医疗保健支出概览：依主要机构划分国家/地区
  • 技术进步、体外诊断设备及试剂盒
  • COVID-19 对体外诊断市场的影响

第五章 全球体外诊断市场分析：洞察与预测 (2021-2034)

  • 市场分析、洞察与预测：依产品类型划分
    • 仪器
    • 试剂和耗材
  • 市场分析、洞察与预测：依技术划分
    • 免疫诊断
      • 酵素连结免疫吸附试验 (ELISA)
      • 萤光免疫分析 (FIA)
      • 快速侦测
      • 其他
    • 临床化学
      • 电解质检测项目
      • 基础与综合代谢检测项目
      • 肝功能检测
      • 肾功能检测
      • 血脂检测
      • 其他
    • 分子诊断
      • 聚合酶炼式反应 (PCR)
      • 原位杂交
      • DNA定序/次世代定序
      • 其他
    • 血液学
    • 其他
  • 市场分析、洞察与预测：按样本类型划分
    • 血液
    • 尿液
    • 唾液
    • 组织
    • 其他
  • 市场分析、洞察与预测：按地点划分
    • 实验室
    • 即时侦测 (POC)
  • 市场分析、洞察、及预测：按应用领域
    • 传染病
    • 心臟病
    • 癌症
    • 消化系统疾病
    • 过敏症
    • 自体免疫疾病
    • 产前筛检
    • 其他
  • 市场分析、洞察及预测：按最终用户
    • 临床实验室
    • 医院
    • 诊所
    • 其他
  • 市场分析、洞察及预测：按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美体外诊断市场分析：洞察与预测（2021-2034）

  • 依国家/地区
    • 美国
    • 加拿大

第七章：欧洲体外诊断市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚半岛
    • 欧洲其他地区

第八章：亚太地区体外诊断市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 其他地区亚太地区

第九章：拉丁美洲体外诊断市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲体外诊断市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会（GCC）成员国
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2025）
  • 主要营运公司概览市场
    • F. Hoffmann-La Roche Ltd.
    • Abbott
    • Thermo Fisher Scientific Inc.
    • Sysmex Corporation
    • Siemens Healthineers AG
    • BD
    • Seegene Inc.
    • DiaSorin S.p.A.
    • Quest Diagnostics Incorporated
    • Bio-Rad Laboratories, Inc.
Product Code: FBI101443

Growth Factors of in-vitro diagnostics (IVD) Market

The global in-vitro diagnostics (IVD) market size was valued at USD 77.73 billion in 2025 and is expected to grow to USD 81.83 billion in 2026, reaching USD 135.65 billion by 2034, exhibiting a CAGR of 6.50% during the forecast period (2026-2034). North America dominated the global IVD market with a 37.70% market share in 2025, supported by advanced healthcare infrastructure, favorable reimbursement policies, and strong presence of major diagnostic manufacturers.

IVD devices are medical diagnostic tools used to analyze biological samples such as blood, urine, saliva, and tissues for disease detection, therapy monitoring, and health screening. According to the British In-Vitro Diagnostic Association, IVD tests influence nearly 70% of clinical decision-making, highlighting their essential role in modern healthcare systems.

Market Drivers

The increasing prevalence of chronic and infectious diseases is a major growth driver. According to the U.S. CDC, tuberculosis cases in the U.S. increased by 5% to 8,300 cases in 2022. Additionally, global prevalence of chronic Hepatitis B virus infection was estimated at 3.2% or 257 million cases in 2023, according to NCBI data.

Aging populations further increase testing volumes. China had approximately 297 million people aged 60 and above in 2023, increasing demand for diagnostic monitoring of cardiovascular, renal, and metabolic disorders. Rising government support also boosts adoption. In October 2023, the World Health Organization released the 2023 Essential Diagnostics List, encouraging countries to strengthen diagnostic access at primary and secondary healthcare levels.

Market Restraints

High equipment and maintenance costs restrict adoption in emerging economies. RT-PCR systems range from USD 15,000 to over USD 90,000, limiting affordability for small hospitals and laboratories. Additionally, skilled personnel requirements raise operational expenses, restricting penetration in low-resource settings.

Market Opportunities

Molecular diagnostics represents a major opportunity due to higher sensitivity and faster detection capabilities. Techniques such as PCR and next-generation sequencing enable early diagnosis from minimal samples. In March 2023, DiaSorin received FDA approval for Simplexa COVID-19 & Flu A/B Direct assay, expanding molecular testing portfolios.

Growing oncology biomarker testing and personalized medicine initiatives further support adoption of advanced diagnostic platforms. Expanding cancer screening programs and genomic testing are increasing molecular diagnostic volumes across developed and emerging regions.

Market Challenges

Unfavorable reimbursement policies limit test adoption in several countries. In Brazil and Mexico, coverage for advanced molecular tests remains insufficient. According to NCBI, Rare Disease Reference Centers provide only USD 142 per patient every three months, insufficient for advanced genomic testing. Regulatory complexity, supply chain disruptions, and intense market competition further increase operational challenges.

Market Trends

Point-of-care (POC) testing is gaining strong traction due to faster turnaround times and lower infrastructure requirements. In January 2023, Cipla launched Cippoint POC device, strengthening decentralized diagnostics. BD received CE approval in June 2022 for combined COVID, Flu, and RSV panels, supporting multiplex testing adoption.

Technological integration of automation and artificial intelligence is improving workflow efficiency, diagnostic accuracy, and sample throughput in clinical laboratories.

Segmentation Analysis

By Product Type

Reagents and consumables dominated in 2024 due to high testing volumes from chronic disease monitoring and POC kits. In February 2021, Thermo Fisher launched TaqPath COVID-19 HT kit for high-throughput testing. Instruments are expected to grow steadily due to automation upgrades, such as BD's FACSDuet Premium Sample Preparation System launched in June 2023.

By Technique

Molecular diagnostics dominated in 2024 due to increasing infectious disease and oncology testing. Seegene received ISO45001 certification in December 2023 for PCR diagnostics. Clinical chemistry also grows steadily due to rising metabolic disease screening.

By Sample

Blood samples dominated in 2024, supported by approximately 2 billion blood tests performed annually in the U.S. Urine and saliva testing volumes are increasing due to non-invasive diagnostic innovations.

By Setting

Laboratories dominated due to complex testing requirements and automation investments. POC settings are growing rapidly due to rapid infectious disease screening and emergency testing.

By Application

Infectious disease diagnostics dominated in 2024. WHO estimated 10.8 million global TB cases in 2023. Oncology diagnostics also show strong growth due to biomarker-based cancer screening expansion.

By End-User

Clinical laboratories dominated in 2024, supported by approximately 322,488 labs operating in the U.S. Hospitals show rising adoption for diabetes, pregnancy, and emergency testing.

Regional Outlook

North America generated USD 29.33 billion in 2025 and USD 30.92 billion in 2026, led by the U.S. reaching USD 27.98 billion in 2026. Europe remains second-largest, with Germany reaching USD 5.50 billion in 2026 and the U.K. at USD 3.83 billion in 2026. Asia Pacific reached USD 18.94 billion in 2026, with China at USD 6.61 billion, Japan at USD 4.32 billion, and India at USD 3.37 billion. Latin America reached USD 6.22 billion in 2026, while GCC markets reached USD 4.25 billion in 2026.

Competitive Landscape

The market is semi-consolidated, led by Roche, Abbott, Siemens Healthineers, Thermo Fisher Scientific, BD, Sysmex, DiaSorin, and Seegene. Companies focus on product innovation, regulatory approvals, and geographic expansion. In November 2023, Roche launched Elecsys HBeAg quant immunoassay, while Abbott partnered with LifeLabs in September 2023 to expand diagnostic service reach.

Conclusion

The global in-vitro diagnostics (IVD) market demonstrates steady and sustainable growth, expanding from USD 77.73 billion in 2025 to USD 81.83 billion in 2026, and projected to reach USD 135.65 billion by 2034, supported by a 6.50% CAGR during 2026-2034. Market expansion is primarily driven by rising prevalence of chronic and infectious diseases, increasing geriatric populations, and strong dependence of clinical decision-making on laboratory diagnostics, which influences nearly 70% of treatment decisions. North America maintains leadership with a 37.70% share in 2025, supported by strong reimbursement systems and advanced diagnostic infrastructure, while Asia Pacific shows rapid growth due to expanding healthcare access and rising disease burden. Segment-wise, reagents and consumables, molecular diagnostics, blood-based testing, and laboratory settings remain dominant due to high testing volumes and increasing automation. Although high instrument costs, reimbursement limitations, and regulatory complexities continue to challenge market penetration in emerging economies, growing adoption of molecular testing, point-of-care diagnostics, AI-enabled systems, and personalized medicine is strengthening long-term demand. Overall, IVD remains a foundational pillar of modern healthcare delivery, enabling early detection, treatment monitoring, and improved population health outcomes across global healthcare systems.

Segmentation By Product Type

  • Instruments
  • Reagents & Consumables

By Technique

  • Immunodiagnostics
    • Enzyme-linked immunosorbent Assays (ELISA)
    • Fluorescence immunoassay (FIA)
    • Rapid test
    • Others
  • Clinical Chemistry
    • Electrolyte Panel
    • Basic and Comprehensive Metabolic Panels
    • Liver Tests
    • Renal Tests
    • Lipid Panel
    • Others
  • Molecular Diagnostics
    • Polymerase Chain Reaction (PCR)
    • In Situ Hybridization
    • DNA Sequencing & Next-Generation Sequencing
    • Others
  • Hematology
  • Others

By Sample

  • Blood
  • Urine
  • Saliva
  • Tissue
  • Others

By Setting

  • Laboratories
  • Point-of-Care

By Application

  • Infectious Diseases
  • Cardiology
  • Oncology
  • Gastroenterology
  • Allergy
  • Autoimmunity
  • Prenatal Screening
  • Others

By End-user

  • Clinical Laboratories
  • Hospitals
  • Physician's Offices
  • Others

By Region

  • North America (By Product Type, By Technique, By Sample, By Setting, By Application, By End-user, and By Country)
    • U.S. (By Setting)
    • Canada (By Setting)
  • Europe (By Product Type, By Technique, By Sample, By Setting, By Application, By End-user, and By Country/Sub-region)
    • Germany (By Setting)
    • U.K. (By Setting)
    • France (By Setting)
    • Italy (By Setting)
    • Spain (By Setting)
    • Scandinavia (By Setting)
    • Rest of Europe (By Setting)
  • Asia Pacific (By Product Type, By Technique, By Sample, By Setting, By Application, By End-user, and By Country/Sub-region)
    • China (By Setting)
    • Japan (By Setting)
    • India (By Setting)
    • Australia (By Setting)
    • Southeast Asia (By Setting)
    • Rest of Asia Pacific (By Setting)
  • Latin America (By Product Type, By Technique, By Sample, By Setting, By Application, By End-user, and By Country/Sub-region)
    • Brazil (By Setting)
    • Mexico (By Setting)
    • Rest of Latin America (By Setting)
  • Middle East & Africa (By Product Type, By Technique, By Sample, By Setting, By Application, By End-user, and By Country/Sub-region)
    • South Africa (By Setting)
    • GCC (By Setting)
  • Rest of Middle East & Africa (By Setting)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Key Diseases, by Countries/Region in 2025
  • 4.2. New Product Launches by Key Players
  • 4.3. Recent Industry Developments - Mergers & Acquisitions
  • 4.4. Overview of Healthcare Expenditure by Key Countries
  • 4.5. Technological Advancements, IVD Instruments & Kits
  • 4.6. Impact of COVID-19 on the In-Vitro Diagnostics Market

5. Global In-Vitro Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. Instruments
    • 5.1.2. Reagents & Consumables
  • 5.2. Market Analysis, Insights and Forecast - By Technique
    • 5.2.1. Immunodiagnostics
      • 5.2.1.1. Enzyme-linked immunosorbent Assays (ELISA)
      • 5.2.1.2. Fluorescence immunoassay (FIA)
      • 5.2.1.3. Rapid test
      • 5.2.1.4. Others
    • 5.2.2. Clinical Chemistry
      • 5.2.2.1. Electrolyte Panel
      • 5.2.2.2. Basic and Comprehensive Metabolic Panels
      • 5.2.2.3. Liver Tests
      • 5.2.2.4. Renal Tests
      • 5.2.2.5. Lipid Panel
      • 5.2.2.6. Others
    • 5.2.3. Molecular Diagnostics
      • 5.2.3.1. Polymerase Chain Reaction (PCR)
      • 5.2.3.2. In Situ Hybridization
      • 5.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 5.2.3.4. Others
    • 5.2.4. Hematology
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Sample Type
    • 5.3.1. Blood
    • 5.3.2. Urine
    • 5.3.3. Saliva
    • 5.3.4. Tissue
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By Setting
    • 5.4.1. Laboratories
    • 5.4.2. Point of care
  • 5.5. Market Analysis, Insights and Forecast - By Application
    • 5.5.1. Infectious Diseases
    • 5.5.2. Cardiology
    • 5.5.3. Oncology
    • 5.5.4. Gastroenterology
    • 5.5.5. Allergy
    • 5.5.6. Autoimmunity
    • 5.5.7. Prenatal Screening
    • 5.5.8. Others
  • 5.6. Market Analysis, Insights and Forecast - By End User
    • 5.6.1. Clinical Laboratories
    • 5.6.2. Hospitals
    • 5.6.3. Physician's Offices
    • 5.6.4. Others
  • 5.7. Market Analysis, Insights and Forecast - By Geography
    • 5.7.1. North America
    • 5.7.2. Europe
    • 5.7.3. Asia Pacific
    • 5.7.4. Latin America
    • 5.7.5. Middle East & Africa

6. North America In-Vitro Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. Instruments
    • 6.1.2. Reagents & Consumables
  • 6.2. Market Analysis, Insights and Forecast - By Technique
    • 6.2.1. Immunodiagnostics
      • 6.2.1.1. Enzyme-linked immunosorbent Assays (ELISA)
      • 6.2.1.2. Fluorescence immunoassay (FIA)
      • 6.2.1.3. Rapid test
      • 6.2.1.4. Others
    • 6.2.2. Clinical Chemistry
      • 6.2.2.1. Electrolyte Panel
      • 6.2.2.2. Basic and Comprehensive Metabolic Panels
      • 6.2.2.3. Liver Tests
      • 6.2.2.4. Renal Tests
      • 6.2.2.5. Lipid Panel
      • 6.2.2.6. Others
    • 6.2.3. Molecular Diagnostics
      • 6.2.3.1. Polymerase Chain Reaction (PCR)
      • 6.2.3.2. In Situ Hybridization
      • 6.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 6.2.3.4. Others
    • 6.2.4. Hematology
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Sample Type
    • 6.3.1. Blood
    • 6.3.2. Urine
    • 6.3.3. Saliva
    • 6.3.4. Tissue
    • 6.3.5. Others
  • 6.4. Market Analysis, Insights and Forecast - By Setting
    • 6.4.1. Laboratories
    • 6.4.2. Point of care
  • 6.5. Market Analysis, Insights and Forecast - By Application
    • 6.5.1. Infectious Diseases
    • 6.5.2. Cardiology
    • 6.5.3. Oncology
    • 6.5.4. Gastroenterology
    • 6.5.5. Allergy
    • 6.5.6. Autoimmunity
    • 6.5.7. Prenatal Screening
    • 6.5.8. Others
  • 6.6. Market Analysis, Insights and Forecast - By End User
    • 6.6.1. Clinical Laboratories
    • 6.6.2. Hospitals
    • 6.6.3. Physician's Offices
    • 6.6.4. Others
  • 6.7. Market Analysis, Insights and Forecast - By Country
    • 6.7.1. U.S.
      • 6.7.1.1. By Setting
    • 6.7.2. Canada
      • 6.7.2.1. By Setting

7. Europe In-Vitro Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. Instruments
    • 7.1.2. Reagents & Consumables
  • 7.2. Market Analysis, Insights and Forecast - By Technique
    • 7.2.1. Immunodiagnostics
      • 7.2.1.1. Enzyme-linked immunosorbent Assays (ELISA)
      • 7.2.1.2. Fluorescence immunoassay (FIA)
      • 7.2.1.3. Rapid test
      • 7.2.1.4. Others
    • 7.2.2. Clinical Chemistry
      • 7.2.2.1. Electrolyte Panel
      • 7.2.2.2. Basic and Comprehensive Metabolic Panels
      • 7.2.2.3. Liver Tests
      • 7.2.2.4. Renal Tests
      • 7.2.2.5. Lipid Panel
      • 7.2.2.6. Others
    • 7.2.3. Molecular Diagnostics
      • 7.2.3.1. Polymerase Chain Reaction (PCR)
      • 7.2.3.2. In Situ Hybridization
      • 7.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 7.2.3.4. Others
    • 7.2.4. Hematology
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Sample Type
    • 7.3.1. Blood
    • 7.3.2. Urine
    • 7.3.3. Saliva
    • 7.3.4. Tissue
    • 7.3.5. Others
  • 7.4. Market Analysis, Insights and Forecast - By Setting
    • 7.4.1. Laboratories
    • 7.4.2. Point of care
  • 7.5. Market Analysis, Insights and Forecast - By Application
    • 7.5.1. Infectious Diseases
    • 7.5.2. Cardiology
    • 7.5.3. Oncology
    • 7.5.4. Gastroenterology
    • 7.5.5. Allergy
    • 7.5.6. Autoimmunity
    • 7.5.7. Prenatal Screening
    • 7.5.8. Others
  • 7.6. Market Analysis, Insights and Forecast - By End User
    • 7.6.1. Clinical Laboratories
    • 7.6.2. Hospitals
    • 7.6.3. Physician's Offices
    • 7.6.4. Others
  • 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.7.1. Germany
      • 7.7.1.1. By Setting
    • 7.7.2. U.K.
      • 7.7.2.1. By Setting
    • 7.7.3. France
      • 7.7.3.1. By Setting
    • 7.7.4. Italy
      • 7.7.4.1. By Setting
    • 7.7.5. Spain
      • 7.7.5.1. By Setting
    • 7.7.6. Scandinavia
      • 7.7.6.1. By Setting
    • 7.7.7. Rest of Europe
      • 7.7.7.1. By Setting

8. Asia Pacific In-Vitro Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. Instruments
    • 8.1.2. Reagents & Consumables
  • 8.2. Market Analysis, Insights and Forecast - By Technique
    • 8.2.1. Immunodiagnostics
      • 8.2.1.1. Enzyme-linked immunosorbent Assays (ELISA)
      • 8.2.1.2. Fluorescence immunoassay (FIA)
      • 8.2.1.3. Rapid test
      • 8.2.1.4. Others
    • 8.2.2. Clinical Chemistry
      • 8.2.2.1. Electrolyte Panel
      • 8.2.2.2. Basic and Comprehensive Metabolic Panels
      • 8.2.2.3. Liver Tests
      • 8.2.2.4. Renal Tests
      • 8.2.2.5. Lipid Panel
      • 8.2.2.6. Others
    • 8.2.3. Molecular Diagnostics
      • 8.2.3.1. Polymerase Chain Reaction (PCR)
      • 8.2.3.2. In Situ Hybridization
      • 8.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 8.2.3.4. Others
    • 8.2.4. Hematology
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Sample Type
    • 8.3.1. Blood
    • 8.3.2. Urine
    • 8.3.3. Saliva
    • 8.3.4. Tissue
    • 8.3.5. Others
  • 8.4. Market Analysis, Insights and Forecast - By Setting
    • 8.4.1. Laboratories
    • 8.4.2. Point of care
  • 8.5. Market Analysis, Insights and Forecast - By Application
    • 8.5.1. Infectious Diseases
    • 8.5.2. Cardiology
    • 8.5.3. Oncology
    • 8.5.4. Gastroenterology
    • 8.5.5. Allergy
    • 8.5.6. Autoimmunity
    • 8.5.7. Prenatal Screening
    • 8.5.8. Others
  • 8.6. Market Analysis, Insights and Forecast - By End User
    • 8.6.1. Clinical Laboratories
    • 8.6.2. Hospitals
    • 8.6.3. Physician's Offices
    • 8.6.4. Others
  • 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.7.1. China
      • 8.7.1.1. By Setting
    • 8.7.2. Japan
      • 8.7.2.1. By Setting
    • 8.7.3. India
      • 8.7.3.1. By Setting
    • 8.7.4. Australia
      • 8.7.4.1. By Setting
    • 8.7.5. Southeast Asia
      • 8.7.5.1. By Setting
    • 8.7.6. Rest of Asia Pacific
      • 8.7.6.1. By Setting

9. Latin America In-Vitro Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. Instruments
    • 9.1.2. Reagents & Consumables
  • 9.2. Market Analysis, Insights and Forecast - By Technique
    • 9.2.1. Immunodiagnostics
      • 9.2.1.1. Enzyme-linked immunosorbent Assays (ELISA)
      • 9.2.1.2. Fluorescence immunoassay (FIA)
      • 9.2.1.3. Rapid test
      • 9.2.1.4. Others
    • 9.2.2. Clinical Chemistry
      • 9.2.2.1. Electrolyte Panel
      • 9.2.2.2. Basic and Comprehensive Metabolic Panels
      • 9.2.2.3. Liver Tests
      • 9.2.2.4. Renal Tests
      • 9.2.2.5. Lipid Panel
      • 9.2.2.6. Others
    • 9.2.3. Molecular Diagnostics
      • 9.2.3.1. Polymerase Chain Reaction (PCR)
      • 9.2.3.2. In Situ Hybridization
      • 9.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 9.2.3.4. Others
    • 9.2.4. Hematology
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Sample Type
    • 9.3.1. Blood
    • 9.3.2. Urine
    • 9.3.3. Saliva
    • 9.3.4. Tissue
    • 9.3.5. Others
  • 9.4. Market Analysis, Insights and Forecast - By Setting
    • 9.4.1. Laboratories
    • 9.4.2. Point of care
  • 9.5. Market Analysis, Insights and Forecast - By Application
    • 9.5.1. Infectious Diseases
    • 9.5.2. Cardiology
    • 9.5.3. Oncology
    • 9.5.4. Gastroenterology
    • 9.5.5. Allergy
    • 9.5.6. Autoimmunity
    • 9.5.7. Prenatal Screening
    • 9.5.8. Others
  • 9.6. Market Analysis, Insights and Forecast - By End User
    • 9.6.1. Clinical Laboratories
    • 9.6.2. Hospitals
    • 9.6.3. Physician's Offices
    • 9.6.4. Others
  • 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.7.1. Brazil
      • 9.7.1.1. By Setting
    • 9.7.2. Mexico
      • 9.7.2.1. By Setting
    • 9.7.3. Rest of Latin America
      • 9.7.3.1. By Setting

10. Middle East & Africa In-Vitro Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product Type
    • 10.1.1. Instruments
    • 10.1.2. Reagents & Consumables
  • 10.2. Market Analysis, Insights and Forecast - By Technique
    • 10.2.1. Immunodiagnostics
      • 10.2.1.1. Enzyme-linked immunosorbent Assays (ELISA)
      • 10.2.1.2. Fluorescence immunoassay (FIA)
      • 10.2.1.3. Rapid test
      • 10.2.1.4. Others
    • 10.2.2. Clinical Chemistry
      • 10.2.2.1. Electrolyte Panel
      • 10.2.2.2. Basic and Comprehensive Metabolic Panels
      • 10.2.2.3. Liver Tests
      • 10.2.2.4. Renal Tests
      • 10.2.2.5. Lipid Panel
      • 10.2.2.6. Others
    • 10.2.3. Molecular Diagnostics
      • 10.2.3.1. Polymerase Chain Reaction (PCR)
      • 10.2.3.2. In Situ Hybridization
      • 10.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 10.2.3.4. Others
    • 10.2.4. Hematology
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Sample Type
    • 10.3.1. Blood
    • 10.3.2. Urine
    • 10.3.3. Saliva
    • 10.3.4. Tissue
    • 10.3.5. Others
  • 10.4. Market Analysis, Insights and Forecast - By Setting
    • 10.4.1. Laboratories
    • 10.4.2. Point of care
  • 10.5. Market Analysis, Insights and Forecast - By Application
    • 10.5.1. Infectious Diseases
    • 10.5.2. Cardiology
    • 10.5.3. Oncology
    • 10.5.4. Gastroenterology
    • 10.5.5. Allergy
    • 10.5.6. Autoimmunity
    • 10.5.7. Prenatal Screening
    • 10.5.8. Others
  • 10.6. Market Analysis, Insights and Forecast - By End User
    • 10.6.1. Clinical Laboratories
    • 10.6.2. Hospitals
    • 10.6.3. Physician's Offices
    • 10.6.4. Others
  • 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.7.1. GCC
      • 10.7.1.1. By Setting
    • 10.7.2. South Africa
      • 10.7.2.1. By Setting
    • 10.7.3. Rest of Middle East & Africa
      • 10.7.3.1. By Setting

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Profiles of Players Operating in the Market
    • 11.2.1. F. Hoffmann-La Roche Ltd.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Abbott
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Thermo Fisher Scientific Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sysmex Corporation
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Siemens Healthineers AG
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. BD
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Seegene Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. DiaSorin S.p.A.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Quest Diagnostics Incorporated
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Bio-Rad Laboratories, Inc.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 2: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 3: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2021-2034
  • Table 4: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2021-2034
  • Table 5: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 6: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Sample Type, 2021-2034
  • Table 7: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 8: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 9: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 10: Global In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 11: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 12: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 13: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2021-2034
  • Table 14: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2021-2034
  • Table 15: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 16: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Sample Type, 2021-2034
  • Table 17: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 18: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 19: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 20: North America In-vitro Diagnostics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 21: U.S. In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 22: Canada In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 23: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 24: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 25: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2021-2034
  • Table 26: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2021-2034
  • Table 27: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 28: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Sample Type, 2021-2034
  • Table 29: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 30: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 31: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 32: Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 33: Germany In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 34: U.K. In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 35: France In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 36: Italy In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 37: Spain In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 38: Scandinavia In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 39: Rest of Europe In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 40: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 41: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 42: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2021-2034
  • Table 43: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2021-2034
  • Table 44: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 45: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Sample Type, 2021-2034
  • Table 46: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 47: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 48: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 49: Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 50: China In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 51: Japan In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 52: India In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 53: Australia In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 54: Southeast Asia In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 55: Rest of Asia Pacific In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 56: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 57: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 58: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2021-2034
  • Table 59: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2021-2034
  • Table 60: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 61: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Sample Type, 2021-2034
  • Table 62: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 63: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 64: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 65: Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 66: Brazil In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 67: Mexico In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 68: Rest of Latin America In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 69: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 70: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 71: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2021-2034
  • Table 72: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2021-2034
  • Table 73: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 74: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Sample Type, 2021-2034
  • Table 75: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 76: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 77: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 78: Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 79: GCC In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 80: South Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 81: Rest of Middle East & Africa In-vitro Diagnostics Market Revenue (USD billion) Forecast, by Setting, 2021-2034

List of Figures

  • Figure 1: Global In-vitro Diagnostics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global In-vitro Diagnostics Market Value Share (%), by Product Type, 2025 & 2034
  • Figure 3: Global In-vitro Diagnostics Market Value Share (%), by Technique, 2025 & 2034
  • Figure 4: Global In-vitro Diagnostics Market Value Share (%), by Sample Type, 2025 & 2034
  • Figure 5: Global In-vitro Diagnostics Market Value Share (%), by Setting, 2025 & 2034
  • Figure 6: Global In-vitro Diagnostics Market Value Share (%), by Application, 2025 & 2034
  • Figure 7: Global In-vitro Diagnostics Market Value Share (%), by End User, 2025 & 2034
  • Figure 8: Global In-vitro Diagnostics Market Value Share (%), by Region, 2025 & 2034
  • Figure 9: North America In-vitro Diagnostics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 10: North America In-vitro Diagnostics Market Value Share (%), by Product Type, 2025
  • Figure 11: North America In-vitro Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 12: North America In-vitro Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 13: North America In-vitro Diagnostics Market Value (USD billion), by Sample Type, 2025 & 2034
  • Figure 14: North America In-vitro Diagnostics Market Value Share (%), by Sample Type, 2025
  • Figure 15: North America In-vitro Diagnostics Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 16: North America In-vitro Diagnostics Market Value Share (%), by Setting, 2025
  • Figure 17: North America In-vitro Diagnostics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 18: North America In-vitro Diagnostics Market Value Share (%), by Application, 2025
  • Figure 19: North America In-vitro Diagnostics Market Value (USD billion), by End User, 2025 & 2034
  • Figure 20: North America In-vitro Diagnostics Market Value Share (%), by End User, 2025
  • Figure 21: North America In-vitro Diagnostics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 22: North America In-vitro Diagnostics Market Value Share (%), By Country, 2025
  • Figure 23: Europe In-vitro Diagnostics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 24: Europe In-vitro Diagnostics Market Value Share (%), by Product Type, 2025
  • Figure 25: Europe In-vitro Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 26: Europe In-vitro Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 27: Europe In-vitro Diagnostics Market Value (USD billion), by Sample Type, 2025 & 2034
  • Figure 28: Europe In-vitro Diagnostics Market Value Share (%), by Sample Type, 2025
  • Figure 29: Europe In-vitro Diagnostics Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 30: Europe In-vitro Diagnostics Market Value Share (%), by Setting, 2025
  • Figure 31: Europe In-vitro Diagnostics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 32: Europe In-vitro Diagnostics Market Value Share (%), by Application, 2025
  • Figure 33: Europe In-vitro Diagnostics Market Value (USD billion), by End User, 2025 & 2034
  • Figure 34: Europe In-vitro Diagnostics Market Value Share (%), by End User, 2025
  • Figure 35: Europe In-vitro Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Europe In-vitro Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Asia Pacific In-vitro Diagnostics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 38: Asia Pacific In-vitro Diagnostics Market Value Share (%), by Product Type, 2025
  • Figure 39: Asia Pacific In-vitro Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 40: Asia Pacific In-vitro Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 41: Asia Pacific In-vitro Diagnostics Market Value (USD billion), by Sample Type, 2025 & 2034
  • Figure 42: Asia Pacific In-vitro Diagnostics Market Value Share (%), by Sample Type, 2025
  • Figure 43: Asia Pacific In-vitro Diagnostics Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 44: Asia Pacific In-vitro Diagnostics Market Value Share (%), by Setting, 2025
  • Figure 45: Asia Pacific In-vitro Diagnostics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 46: Asia Pacific In-vitro Diagnostics Market Value Share (%), by Application, 2025
  • Figure 47: Asia Pacific In-vitro Diagnostics Market Value (USD billion), by End User, 2025 & 2034
  • Figure 48: Asia Pacific In-vitro Diagnostics Market Value Share (%), by End User, 2025
  • Figure 49: Asia Pacific In-vitro Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 50: Asia Pacific In-vitro Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 51: Latin America In-vitro Diagnostics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 52: Latin America In-vitro Diagnostics Market Value Share (%), by Product Type, 2025
  • Figure 53: Latin America In-vitro Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 54: Latin America In-vitro Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 55: Latin America In-vitro Diagnostics Market Value (USD billion), by Sample Type, 2025 & 2034
  • Figure 56: Latin America In-vitro Diagnostics Market Value Share (%), by Sample Type, 2025
  • Figure 57: Latin America In-vitro Diagnostics Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 58: Latin America In-vitro Diagnostics Market Value Share (%), by Setting, 2025
  • Figure 59: Latin America In-vitro Diagnostics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 60: Latin America In-vitro Diagnostics Market Value Share (%), by Application, 2025
  • Figure 61: Latin America In-vitro Diagnostics Market Value (USD billion), by End User, 2025 & 2034
  • Figure 62: Latin America In-vitro Diagnostics Market Value Share (%), by End User, 2025
  • Figure 63: Latin America In-vitro Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 64: Latin America In-vitro Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 65: Middle East & Africa In-vitro Diagnostics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 66: Middle East & Africa In-vitro Diagnostics Market Value Share (%), by Product Type, 2025
  • Figure 67: Middle East & Africa In-vitro Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 68: Middle East & Africa In-vitro Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 69: Middle East & Africa In-vitro Diagnostics Market Value (USD billion), by Sample Type, 2025 & 2034
  • Figure 70: Middle East & Africa In-vitro Diagnostics Market Value Share (%), by Sample Type, 2025
  • Figure 71: Middle East & Africa In-vitro Diagnostics Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 72: Middle East & Africa In-vitro Diagnostics Market Value Share (%), by Setting, 2025
  • Figure 73: Middle East & Africa In-vitro Diagnostics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 74: Middle East & Africa In-vitro Diagnostics Market Value Share (%), by Application, 2025
  • Figure 75: Middle East & Africa In-vitro Diagnostics Market Value (USD billion), by End User, 2025 & 2034
  • Figure 76: Middle East & Africa In-vitro Diagnostics Market Value Share (%), by End User, 2025
  • Figure 77: Middle East & Africa In-vitro Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 78: Middle East & Africa In-vitro Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 79: Global In-vitro Diagnostics Market Share (%), By Company, 2025